BioPharmSignal logoBioPharmSignal

Biotech News

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Atea (AVIR)AteaEarnings

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD,

Related news

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ENTAEnanta Pharmaceuticals2025-11-17 21:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

COCPCocrystal Pharma2025-11-14 13:00 EST

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

IMNNImunon2025-11-13 12:45 EST

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

ABUSArbutus2025-11-13 12:30 EST

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ANTXAN2 Therapeutics2025-11-12 21:01 EST

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

ASMBAssembly Biosciences2025-11-10 21:09 EST

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

BRNSBarinthus Biotherapeutics2025-11-07 12:30 EST

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

View all latest news

Atea

Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers...

Recent company news

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

AVIRAtea2026-06-25 11:00 EST

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Stock data

Close
4.99 USD
Market cap
341.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States